Telomir Pharmaceuticals, Inc. (TELO) Stock Price & Analysis
Telomir Pharmaceuticals, Inc. (TELO) fell 5.47% to USD 1.21 as of June 10, 2026 at 01:10 UTC, according to Nexqual real-time market data.
TELO last closed at USD 1.28; the session ranged USD 1.21–1.28 on volume of 52,611 shares. Market capitalization is $83.22M, with a 52-week range of USD 1.05–3.1 (NCM). Source: Nexqual, June 10, 2026 at 01:10 UTC.
Key Statistics (as of June 10, 2026 at 01:10 UTC)
| Price | USD 1.21 |
|---|---|
| Change | ▼ 5.47% (down) |
| Previous Close | USD 1.28 |
| Open | USD 1.28 |
| Day Range | USD 1.21 – 1.28 |
| 52-Week Range | USD 1.05 – 3.1 |
| Volume | 52,611 shares |
| Market Cap | $83.22M |
| Exchange | NCM |
Technical Analysis (TELO)
Nexqual's technical model rates TELO "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:10 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.49 (neutral) |
| vs SMA50 | Below (USD 1.31) |
| MACD | -0.02 (negative) |
Analyst Ratings (TELO)
Wall Street analysts rate TELO "None", per Nexqual as of June 10, 2026 at 01:10 UTC.
| Consensus Rating | None |
|---|
Earnings (TELO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.03 vs est -0.07 ▲ beat |
| 2025-06-30 | USD -0.17 vs est -0.08 ▼ miss |
| 2025-03-31 | USD -0.07 vs est -0.1 ▲ beat |
| 2024-12-31 | USD -0.1 vs est -0.05 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:10 UTC.
Financials & Fundamentals (TELO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -384.26% |
| Debt / Equity | 4.09 |
| Current Ratio | 7 |
| Total Cash | $5.56M |
| Total Debt | $202,869 |
| Free Cash Flow | $184,064 |
Source: Nexqual, June 10, 2026 at 01:10 UTC.
Financial Health Score (TELO)
Nexqual rates Telomir Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M |
| Efficiency | Critical — ROE -384%, ROA -186.9% |
Ownership (TELO)
| Insider Ownership | +35.10% |
|---|---|
| Institutional Ownership | +3.26% |
| Shares Outstanding | 68.77M |
| Float | 38.06M |
| Short % of Float | +1.89% |
Source: Nexqual, June 10, 2026 at 01:10 UTC.
Leadership (TELO)
Telomir Pharmaceuticals, Inc. is led by Erez Aminov (age 46), Chairman of the Board & CEO, per Nexqual as of June 10, 2026 at 01:10 UTC.
| Chairman of the Board & CEO | Erez Aminov (age 46) |
|---|---|
| Chief Scientific Advisor | Itzchak Angel |
Major Backers & Investors (TELO)
Notable institutional backers of Telomir Pharmaceuticals, Inc. include Fidelity, Millennium Management, according to Nexqual as of June 10, 2026 at 01:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.29% |
| Millennium Management | 0.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.1% |
| BlackRock | 0.48% |
| Geode Capital | 0.36% |
Source: Nexqual, June 10, 2026 at 01:10 UTC.
From Telomir Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
- It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MIRA | MIRA Pharmaceuticals, Inc. | USD 0.98 | ▼ 2.3% |
| SUGP | SU Group Holdings Limited | USD 1 | ▲ 0.4% |
| KAPA | Kairos Pharma, Ltd. | USD 0.43 | ▼ 2.05% |
| PLRZ | Polyrizon Ltd. | USD 11.45 | ▼ 11.86% |
| CWD | CaliberCos Inc. | USD 0.85 | ▲ 0.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:10 UTC. This page is informational and not investment advice.